Coologics Raises $3M in Seed Funding
Summary
The round was led by Prevail and Dream Ventures with participation from two university alumni groups, Ohio State Early Investor Network and Illinois Ventures Illini Angels Program. The company intends to use the funds to accelerate the completion of their ongoing clinical trial, FDA submission and initial market release of their flagship product, Vlisse. Led by Founder and CEO Dr. Kim Langdon, Coologics offers sustainable treatments that reduce the unnecessary use of antibiotics, addressing the growing concern of antibiotic resistance. Vlisse is a drug-free intravaginal cooling device designed to treat vaginal infections, including VVC, BV, and mixed infections by leveraging its patented cooling mechanism. This approach focuses on restoring the vaginal environment to a healthy state without the use of chemicals.